FDA批准预填充自动注射器Fasenra治疗哮喘

2019-10-05 Allan MedSci原创

阿斯利康近日宣布,FDA已批准预填充自动注射器Fasenra(benralizumab)治疗严重嗜酸性粒细胞性哮喘,通过这项疗法,患者可以进行自我管理。该公司指出,Fasenra最初于2017年在美国获得批准,用于治疗具有嗜酸性表型的12岁及以上的重度哮喘患者。

阿斯利康近日宣布,FDA已批准预填充自动注射器Fasenra(benralizumab)治疗严重嗜酸性粒细胞性哮喘,通过这项疗法,患者可以进行自我管理。该公司指出,Fasenra最初于2017年在美国获得批准,用于治疗具有嗜酸性表型的12岁及以上的重度哮喘患者。

阿斯利康公司生物制药研发执行副总裁Mene Pangalos表示:“Fasenra是唯一在初始加载剂量后每八周就可以服用的呼吸道生物制剂。这项批准意味着重度嗜酸性哮喘患者可以便捷地使用Fasenra”。该公司还指出,继7月份欧洲药品管理局(EMA)人用药品委员会的正面评价之后,欧盟已批准预填充自动注射器Fasenra治疗哮喘。


原始出处:

http://www.firstwordpharma.com/node/1671730#axzz61Rlned4y

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-09-03 gracezdd
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
    2020-08-01 bugit
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057983, encodeId=90fc205e98360, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Thu Sep 03 20:40:00 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839727, encodeId=573f1839e27be, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat Aug 01 20:40:00 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701480, encodeId=ab6f1e0148057, content=<a href='/topic/show?id=28b7649e927' target=_blank style='color:#2F92EE;'>#注射器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64979, encryptionId=28b7649e927, topicName=注射器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bac630379418, createdName=marongnuan, createdTime=Wed Apr 29 14:40:00 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271171, encodeId=c51b12e1171d1, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Mon Oct 07 02:40:00 CST 2019, time=2019-10-07, status=1, ipAttribution=)]

相关资讯

阿斯利康的Fasenra未达到晚期COPD研究的主要目标

阿斯利康公司周五(2018年5月11日)报道,用于中度至极重度慢性阻塞性肺疾病(COPD)患者治疗的Fasenra(benralizumab)的III期GALATHEA研究未能达到显著降低症状的主要终点

NEJM:Fasenra符合嗜酸性粒细胞增多症中期研究的主要目标

阿斯利康近日表示,在《NEJM》发表的II期研究结果表明,大部分接受Fasenra(贝那利珠单抗)治疗的嗜酸性粒细胞增多症(HES)患者的绝对血液嗜酸性粒细胞计数至少下降一半。

嗜酸性粒细胞性食管炎:Fasenra被FDA授予孤儿药物资格

阿斯利康近日宣布,美国FDA已经授予其Fasenra(贝那利珠单抗)孤儿药物资格,用以治疗嗜酸性粒细胞性食管炎。

欧盟批准AZ的Fasenra治疗严重哮喘

阿斯利康(AstraZeneca)的biologic Fasenra在欧洲被批准用于治疗严重嗜酸粒细胞性哮喘。具体而言,尽管高剂量吸入皮质类固醇加长效β受体激动剂,但该药物的标签允许其在成人中的使用得到充分控制。阿斯利康说,Fasenra(benralizumab)是第一个获得批准的呼吸类生物制剂,它是一种招募自然杀伤细胞以消耗嗜酸性粒细胞的单克隆抗体,在体内维持药效的时间长达八周。批准是基于WI